派思股份(603318.SH)終止2019年非公開發行A股事項並撤回申請材料
格隆匯6月8日丨派思股份(603318.SH)公佈,本次非公開發行股票募集資金用途主要用於收購股權,受疫情影響,公司與主要募投項目交易對手方上海華彗曙智能源發展有限公司就標的資產估值調整進行協商,但未能達成一致。同時,考慮到資本市場環境變化、監管政策變化、公司二級市場估值情況,並結合公司實際情況,為能更好地開展後續公司戰略部署,營造更優的融資方案,進而促使業務更優更快進一步發展,公司經審慎分析並與中介機構等反覆溝通,擬終止2019年度非公開發行A股股票事項,並向中國證監會申請撤回本次非公開發行A股股票的申請文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.